Supotaria Convicap Dry Powder Inhaler

Maintenance bronchodilator treatment to relieve symptoms in adult patients with, chronic obstructive pulmonary disease (COPD)

Inhalation Dry Powder Inhaler Capsule The recommended dosage of Glycopyrronium inhalation: One capsule once daily with the specific inhaler device at the same time of day. Nebulization One ampoule twice daily with nebuliser device. Should be administered at the same time of the day (1 ampoule in the morning and 1 ampoule in the evening).

Hypersensitivity to the active substance or to any of the excipients.

Glycopyrronium should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of Glycopyrronium inhalation powder. As with other anticholinergic drugs, Glycopyrronium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.

Not Classi Pregnancy There are no adequate and well-controlled studies in humans Animal studies have not shown teratogenicity Lactation Unknown if distributed in human breast milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Inhaled medicines may cause inhalation-induced bronchospasm, dehydration, dry mouth, constipation, dizziness, insomnia, skin and subcutaneous tissue disorders, immune system disorders.

Glycopyrronium is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3-receptors at the smooth muscle results in relaxation.

Supotaria Convicap 50mcg Dry Powder Inhaler manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Glycopyrronium bromide (Glycopyrrolate) Inhalation.